These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31533238)

  • 1. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
    Aashiq M; Silverman DA; Na'ara S; Takahashi H; Amit M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31533238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 3. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
    Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
    Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
    [No Abstract]   [Full Text] [Related]  

  • 5. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Inverse Agonist of Estrogen-Related Receptor Gamma, GSK5182, Enhances Na
    Singh TD; Lee JE; Son KH; Lee BR; Kim SK; Gulwani D; Sarangthem V; Jeon YH
    Cells; 2023 Feb; 12(3):. PubMed ID: 36766812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 8. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 10. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells
    Zhang L; Xu S; Cheng X; Wu J; Wang X; Wu L; Yu H; Bao J
    Food Funct; 2021 Sep; 12(18):8260-8273. PubMed ID: 34323243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells.
    Faria M; Domingues R; Bugalho MJ; Matos P; Silva AL
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34831012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers.
    Oh JM; Rajendran RL; Gangadaran P; Hong CM; Jeong JH; Lee J; Ahn BC
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy.
    Dotinga M; Vriens D; van Velden F; Heijmen L; Nagarajah J; Hicks R; Kapiteijn E; de Geus-Oei LF
    Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):250-264. PubMed ID: 32744039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
    Zhang H; Chen D
    Thyroid Res; 2018; 11():13. PubMed ID: 30337961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 18. Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system.
    Oh JM; Kalimuthu S; Gangadaran P; Baek SH; Zhu L; Lee HW; Rajendran RL; Hong CM; Jeong SY; Lee SW; Lee J; Ahn BC
    Oncotarget; 2018 Jan; 9(6):7075-7087. PubMed ID: 29467951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
    Montes de Jesus FM; Espeli V; Paone G; Giovanella L
    Endocrine; 2023 Sep; 81(3):450-454. PubMed ID: 37191938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer.
    Colombo C; Minna E; Gargiuli C; Muzza M; Dugo M; De Cecco L; Pogliaghi G; Tosi D; Bulfamante G; Greco A; Fugazzola L; Borrello MG
    J Exp Clin Cancer Res; 2020 Nov; 39(1):245. PubMed ID: 33198784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.